OPR - Delayed Quote • USD VERU Jan 2025 17.000 call (VERU250117C00017000) Follow 0.0100 0.0000 (0.00%) At close: November 20 at 1:13 PM EST Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for VERU250117C00017000 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: VERU Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11 What Makes Veru (VERU) a New Buy Stock Veru Announces Date of 2024 Annual Meeting of Shareholders Veru Reschedules Annual Meeting of Shareholders Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss After Plunging -15.61% in 4 Weeks, Here's Why the Trend Might Reverse for Veru Inc. (VERU) Veru Inc. (NASDAQ:VERU) Q1 2024 Earnings Call Transcript Q1 2024 Veru Inc Earnings Call Veru Reports Fiscal 2024 First Quarter Financial Highlights Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs
